Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1Carcinoma, Medullary 1

Interventions

Zoledronic Acid 5Bevacizumab 3exemestane 2Therapeutics 2Standard of Care 2Pamidronate 2Oxaliplatin 2Misoprostol 2Magnetic Resonance Spectroscopy 2Letrozole 2Ibandronic Acid 2Fulvestrant 2Fluorouracil 2Cetuximab 2Capecitabine 2vandetanib 1palbociclib 1liposomal doxorubicin 1huaier 1eribulin 1enzalutamide 1darolutamide 1cabozantinib 1aldesleukin 1abemaciclib 1Vindesine 1Trastuzumab 1Sugars 1Stents 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasm Metastasis × vandetanib × Clear all
NCT01496313 2025-10-03

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Sanofi

Phase 4 Completed
81 enrolled 15 charts
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡